Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Tegaserod

Criteria

Inclusion Criteria:

• Female, 18 years and older

• Fulfilled eligibility criteria in CHTF919D2301 (double blind study) and successfully completed the double-blind study

Exclusion Criteria:

• Early discontinuation from the double-blind study

Other protocol-defined inclusion/exclusion criteria may apply